The record
| Class | vascular bioregulator |
|---|---|
| Also known as | KED peptide, Lysylglutamyl aspartic acid, AC-2 |
| Chain length | - |
| Molecular weight | 390.39 Da |
| Half-life | Short (tripeptide - minutes to hours) |
| Route | SC, oral (capsules), sublingual |
| Studied for | Atherosclerosis; Vascular dysfunction; Microcirculation disorders; Age-related vascular decline |
| Research use | Vascular aging; Endothelial function; Neuroprotection |
| What has been shown | Protects endothelial cells; Reduces atherosclerosis markers; Increases RBC membrane stability; Neuroprotective effects on dendritic spines |
| How it works | Synthetic tripeptide bioregulator targeting vascular endothelium. Interacts with DNA at promoter regions, particularly Ki-67 gene, to stimulate endothelial cell proliferation. Regulates SIRT1 protein levels (mimicking calorie restriction effects). Binds DNA minor groove via hydrogen bonds. Modifies lipoprotein structure to restrict lipid peroxidation. Does not have direct antioxidant activity but |
| Patent status | Russian patents |
| Regulatory status | research; approved as supplement in Russia |
Blank = not established in the record. Nothing is estimated to fill a gap.
Where it is matched
- Neuroprotection Signaling (affection, 37%)
- Oxidative Stress Resilience (affection, 42%)
- Vascular / Endothelial Support (affection, 58%)
- Acetaminophen toxicity (illness, 30%)
- Age-related vascular decline (illness, 100%)
- Antioxidant supplementation (illness, 30%)
- Atherosclerosis (illness, 100%)
- Detoxification support (illness, 30%)
- Erythropoietic protoporphyria - FDA approved (illness, 30%)
- Microcirculation disorders (illness, 100%)
- Polymorphous light eruption (illness, 30%)
- Skin lightening (illness, 30%)
- Solar urticaria (illness, 30%)
- Vascular dysfunction (illness, 100%)
- Vitiligo (illness, 30%)
- Poor circulation or cold extremities (symptom, 50%)